IL208296A0 - Alzheimer's disease-specific alterations of the erk1/erk2 phosphorylation ratio-alzheimer's disease-specific molecular biomarkers (adsmb) - Google Patents

Alzheimer's disease-specific alterations of the erk1/erk2 phosphorylation ratio-alzheimer's disease-specific molecular biomarkers (adsmb)

Info

Publication number
IL208296A0
IL208296A0 IL208296A IL20829610A IL208296A0 IL 208296 A0 IL208296 A0 IL 208296A0 IL 208296 A IL208296 A IL 208296A IL 20829610 A IL20829610 A IL 20829610A IL 208296 A0 IL208296 A0 IL 208296A0
Authority
IL
Israel
Prior art keywords
alzheimer
disease
specific
adsmb
erk1
Prior art date
Application number
IL208296A
Other languages
English (en)
Original Assignee
Brni Neurosciences Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/078,857 external-priority patent/US20080221042A1/en
Application filed by Brni Neurosciences Inst filed Critical Brni Neurosciences Inst
Publication of IL208296A0 publication Critical patent/IL208296A0/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL208296A 2008-04-07 2010-09-21 Alzheimer's disease-specific alterations of the erk1/erk2 phosphorylation ratio-alzheimer's disease-specific molecular biomarkers (adsmb) IL208296A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12/078,857 US20080221042A1 (en) 2005-10-11 2008-04-07 Alzheimer's disease-specific alterations of the ERK1/ERK2 Phosphorylation ratio-Alzheimer's disease-specific molecular biomarkers (ADSMB)
PCT/US2009/002120 WO2009126232A1 (en) 2008-04-07 2009-04-03 Alzheimer's disease-specific alterations of the erk1/erk2 phosphorylation ratio-alzheimer's disease-specific molecular biomarkers (adsmb)

Publications (1)

Publication Number Publication Date
IL208296A0 true IL208296A0 (en) 2010-12-30

Family

ID=41037627

Family Applications (1)

Application Number Title Priority Date Filing Date
IL208296A IL208296A0 (en) 2008-04-07 2010-09-21 Alzheimer's disease-specific alterations of the erk1/erk2 phosphorylation ratio-alzheimer's disease-specific molecular biomarkers (adsmb)

Country Status (9)

Country Link
EP (1) EP2263090A1 (zh)
JP (1) JP2011516883A (zh)
KR (1) KR20100132997A (zh)
AU (1) AU2009234405A1 (zh)
BR (1) BRPI0911073A2 (zh)
CA (1) CA2720621A1 (zh)
IL (1) IL208296A0 (zh)
TW (1) TW200942819A (zh)
WO (1) WO2009126232A1 (zh)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3090261B8 (en) * 2014-01-03 2019-06-26 The West Virginia University Board of Governors on behalf of West Virginia University Convergence of aggregation rate with validated peripheral diagnostics for alzheimer's disease
US11415574B2 (en) 2017-03-31 2022-08-16 NeuroDiagnostics LLC Lymphocyte-based morphometric test for alzheimer's disease

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007043998A1 (en) * 2005-10-11 2007-04-19 Blanchette Rockefeller Neurosciences Institute Alzheimer’s disease-specific alterations of the erk1/erk2 phosphorylation ratio

Also Published As

Publication number Publication date
TW200942819A (en) 2009-10-16
AU2009234405A1 (en) 2009-10-15
KR20100132997A (ko) 2010-12-20
JP2011516883A (ja) 2011-05-26
BRPI0911073A2 (pt) 2019-09-24
WO2009126232A1 (en) 2009-10-15
EP2263090A1 (en) 2010-12-22
CA2720621A1 (en) 2009-10-15

Similar Documents

Publication Publication Date Title
EP2349962A4 (en) METHOD FOR PRODUCING HYDROCHLORO FLUOROLEFINES
HK1120288A1 (en) Processes for the manufacture of sterilized pancreatin powder
EP2128178A4 (en) RESIN COMPOSITION FOR OPTICAL ELEMENT AND OPTICAL ELEMENT OBTAINED THEREFROM
HK1160664A1 (zh) 用於產生腺病毒載體的方法
IL202046A0 (en) Process for the manufacture of p4o6
PL2091766T3 (pl) Osłona harmonijkowa
IL196403A0 (en) Processes for the synthesis of o-desmethylvenlafaxine
GB0708014D0 (en) Process for the manufacture of a polymer composition
IL208296A0 (en) Alzheimer's disease-specific alterations of the erk1/erk2 phosphorylation ratio-alzheimer's disease-specific molecular biomarkers (adsmb)
PL1752276T3 (pl) Sposób wytwarzania zorientowanych taśm polimerowych
GB0721309D0 (en) An entity
IL194330A0 (en) Processes for the synthesis of 3-isobutylglutaric acid
IL184221A0 (en) Process for the manufacture of taurine
PL381173A1 (pl) Sposób wytwarzania nanokompozytów polimerowych
IL206612A0 (en) Novel imidazolinylmethyl aryl sulfonamides
PL381556A1 (pl) Sposób otrzymywania modyfikowanych (poli)siloksanów
IL196405A0 (en) Processes for the synthesus of o-desmethylvenlafaxine
GB2457671B (en) Revocation for direct anonymous attestation
GB0503428D0 (en) Moulding of polymers
ZA200903778B (en) Molded part, and methor for the production of the molded part
GB0621214D0 (en) Resin & aggregate mouldings
PL380473A1 (pl) Sposób wytwarzania modyfikowanego kaolinu
GB0720940D0 (en) The modification of aqueos for glass
AU2008905035A0 (en) Alzheimer's disease biomarkers
AU2008901006A0 (en) Hydrogels derived from biological polymers